Click Therapeutics

Click Therapeutics is a biotechnology startup that operates in the digital health sector, specifically in the emerging field of digital therapeutics. The company develops, validates, and commercializes software as prescription medical treatments for patients with unmet medical needs. This means they create software applications that are used like medicine, either on their own or alongside traditional treatments, to help patients manage their health conditions.

The company's business model is based on the development of these software applications, which are designed to alter the cognitive and neurobehavioral mechanisms that underlie various diseases. These applications are rigorously tested through randomized, controlled trials to ensure their safety and effectiveness. Once validated, the company seeks clearance from the FDA to market these apps as class II medical devices.

Click Therapeutics' revenue comes from physicians who prescribe their apps and from payers who reimburse for them. The company also uses real-world evidence to continuously improve and personalize their applications.

One of their notable collaborations is with Boehringer Ingelheim, a leading pharmaceutical company, to develop and commercialize a novel prescription digital therapeutic to aid in the treatment of schizophrenia. This partnership is worth $500 million, indicating the significant potential of digital therapeutics in the healthcare market.

The company's leadership team includes CEO David B. Klein, CFO, CTO, Chief Strategy Officer Austin C. Speier, and Chief Medical Officer Shaheen Lakhan, MD, PhD, FAAN, among others.

Keywords: Digital Therapeutics, Biotechnology, Software as Medical Device, Prescription Software Applications, FDA Clearance, Cognitive Mechanisms, Neurobehavioral Mechanisms, Randomized Controlled Trials, Real-World Evidence, Healthcare Collaboration.